Literature DB >> 11260813

Two behavioral treatments for smoking reduction: a pilot study.

R L Riggs1, J R Hughes, J L Pillitteri.   

Abstract

This study compared two behavioral treatments on their efficacy and acceptability in reducing smoking, using a crossover design with interposed return to baseline, 2 weeks/condition. 20 US cigarette smokers reporting an interest in reducing, but not quitting, their smoking either increased the inter-cigarette interval or selected easy cigarettes to eliminate, with a goal of 50% reduction. Nicotine gum accompanied both treatments. Measurements taken were self-reported cigarettes per day, carbon monoxide, cotinine, and thiocyanate; self-rated acceptability of the treatments; adverse events. Both treatments decreased self-reported cigarettes per day (-45% and -38%) and carbon monoxide (-20% and -19%), but not cotinine or thiocyanate. Increasing the inter-cigarette interval produced slightly more reduction in cigarettes per day than cigarette selection, but no other differences were found. Both treatments were acceptable and safe. Although our sample size was small and the duration of reduction documented short, both treatments appear to be acceptable and efficacious behavioral treatments for reduction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260813     DOI: 10.1080/14622200020032114

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  16 in total

Review 1.  The feasibility of smoking reduction: an update.

Authors:  John R Hughes; Matthew J Carpenter
Journal:  Addiction       Date:  2005-08       Impact factor: 6.526

Review 2.  Does the Magnitude of Reduction in Cigarettes Per Day Predict Smoking Cessation? A Qualitative Review.

Authors:  Elias M Klemperer; John R Hughes
Journal:  Nicotine Tob Res       Date:  2015-03-05       Impact factor: 4.244

3.  Efficacy of a Texting Program to Promote Cessation Among Pregnant Smokers: A Randomized Control Trial.

Authors:  Kathryn I Pollak; Pauline Lyna; Xiaomei Gao; Devon Noonan; Santiago Bejarano Hernandez; Sonia Subudhi; Geeta K Swamy; Laura J Fish
Journal:  Nicotine Tob Res       Date:  2020-06-12       Impact factor: 4.244

4.  Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial.

Authors:  John R Hughes; Stephen I Rennard; James R Fingar; Sandy K Talbot; Peter W Callas; Karl O Fagerstrom
Journal:  Nicotine Tob Res       Date:  2011-06-07       Impact factor: 4.244

5.  Chronic disease management for tobacco dependence: a randomized, controlled trial.

Authors:  Anne M Joseph; Steven S Fu; Bruce Lindgren; Alexander J Rothman; Molly Kodl; Harry Lando; Brandon Doyle; Dorothy Hatsukami
Journal:  Arch Intern Med       Date:  2011-11-28

6.  Working alliance and empathy as mediators of brief telephone counseling for cigarette smokers who are not ready to quit.

Authors:  Elias M Klemperer; John R Hughes; Peter W Callas; Laura J Solomon
Journal:  Psychol Addict Behav       Date:  2017-02

7.  Motivational, reduction and usual care interventions for smokers who are not ready to quit: a randomized controlled trial.

Authors:  Elias M Klemperer; John R Hughes; Laura J Solomon; Peter W Callas; James R Fingar
Journal:  Addiction       Date:  2016-10-05       Impact factor: 6.526

8.  How Do Light and Intermittent Smokers Differ from Heavy Smokers in Young Adulthood: The Role of Smoking Restraint Strategies.

Authors:  Johannes Thrul; Stuart G Ferguson; Anneke Bühler
Journal:  J Psychoactive Drugs       Date:  2016-04-27

9.  The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.

Authors:  Teresa R Franklin; Derek Harper; Kyle Kampman; Susan Kildea-McCrea; Will Jens; Kevin G Lynch; Charles P O'Brien; Anna Rose Childress
Journal:  Drug Alcohol Depend       Date:  2009-04-23       Impact factor: 4.492

10.  Community tobacco control leaders' perceptions of harm reduction.

Authors:  A M Joseph; D Hennrikus; M J Thoele; R Krueger; D Hatsukami
Journal:  Tob Control       Date:  2004-06       Impact factor: 7.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.